MRVI
Maravai LifeSciences Holdings, Inc.NASDAQHealthcare$2.95+2.79%ClosedMarket Cap: $810.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.02
P/S
4.36
EV/EBITDA
-4.28
DCF Value
$2.55
FCF Yield
-8.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
18.0%
Operating Margin
-3.6%
Net Margin
-70.4%
ROE
-51.1%
ROA
-26.7%
ROIC
-0.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $49.9M | 24.5% | $-6.7M | $-35.7M | $-0.25 | — |
| FY 2025 | $185.7M | 18.0% | $-6.7M | $-130.8M | $-0.91 | — |
| Q3 2025 | $41.6M | 13.6% | $115.4M | $-25.6M | $-0.18 | — |
| Q2 2025 | $47.4M | 16.4% | $-66.3M | $-39.6M | $-0.27 | — |
| Q1 2025 | $46.9M | 16.5% | $-49.2M | $-29.9M | $-0.21 | — |
| Q4 2024 | $56.4M | 33.6% | $-38.1M | $-26.1M | $-0.18 | — |
| FY 2024 | $259.2M | 41.8% | $-235.6M | $-144.8M | $-1.05 | — |
| Q3 2024 | $65.2M | 43.5% | $-169.1M | $-99.0M | $-0.70 | — |
| Q2 2024 | $73.4M | 47.9% | $-9.5M | $-7.6M | $-0.06 | — |
| Q1 2024 | $64.2M | 40.3% | $-18.9M | $-12.1M | $-0.09 | — |
| Q4 2023 | $74.1M | 52.6% | $-7.2M | $-106.0M | $-0.80 | — |
| FY 2023 | $288.9M | 48.5% | $-31.6M | $-119.0M | $-0.90 | — |